Canaccord raised the firm’s price target on Extendicare (EXETF) to C$22.50 from C$20 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXETF:
- Extendicare price target raised to C$24.50 from C$21.50 at National Bank
- Extendicare upgraded to Outperform from Sector Perform at RBC Capital
- Extendicare resumed with Outperform from Market Perform at BMO Capital
- Extendicare’s Strategic Acquisition of CBI Home Health: A Catalyst for Growth and Investment Opportunity
- Extendicare Completes $200 Million Private Placement to Fund Strategic Acquisition